Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088.
Turcu AF, Nanba AT, Chomic R, et al. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur J Endocrinol. 2016;174(5):601-609.
[5]
Nhlanhla TY, Kinvig H, Pillay K, et al. Adrenogenital syndrome in adults: A case series and review. J Endocrinol Invest. 2019;42(10):1171-1180.
[6]
Mermejo LM, Elias LL, Marui S, et al. Refining hormonal and genetic testing for diagnosing 21-hydroxylase deficiency: A Brazilian multicenter study. Clin Endocrinol (Oxf). 2018;89(4):459-468.
[7]
Falhammar H, Torpy DJ. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A cross-sectional study of factors influencing quality of life. Clin Endocrinol (Oxf). 2018;88(4):552-559.
[8]
Auchus RJ. Management of congenital adrenal hyperplasia in adults. Curr Opin Endocrinol Diabetes Obes. 2018;25(3):200-206.
[9]
Bachelot A, Plu-Bureau G, Bloch C, et al. Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res. 2017;67(5):268-276.
[10]
Krone N, Haney A, Hauffa BP, et al. Management of congenital adrenal hyperplasia in childhood, adolescence and adulthood. Dtsch Arztebl Int. 2018;115(22):377-383.